Biotech Venture Builder | 4x NAV Growth Since 2023 | $7M Raise, 60%+ Secured

 


Negev Labs – Breakthrough Neurotherapies, 4x NAV Growth

Investment Highlights

  • Sector: Biotech/Neuroplasticity – Addressing multi-billion-dollar opportunities in cognitive and emotional health

  • Business Model: Venture builder model, focused on B2B partnerships, spin-outs, and licensing strategies

  • Board and Management Track Record: Led by a team with deep expertise in biopharma innovation, neuroplasticity research, and successful company building

  • Clients: Two proto-companies, Ariadne Bio (Parkinson’s) and Athena Neurosciences (ADHD), launching in 2025

  • Shareholders: Over 60% of the current $7M raise already secured by professional investors

  • Traction Metrics: Deployed $5M across seven programs, achieving a net asset valuation (NAV) of $23M (4x growth since early 2023)

Executive Summary


Negev Labs is redefining biotech venture building, advancing safe, non-hallucinogenic neurotherapies targeting cognitive and emotional health. With a capital-efficient, risk-mitigated model inspired by leaders like Flagship Pioneering, we leverage rediscovered clinical data to rapidly achieve key milestones. Our $5M investment across seven programs has generated a $23M NAV as of December 2024. Now, we are closing a $7M funding round—already over 60% secured—to propel the launch of Ariadne Bio (Parkinson’s disease) and Athena Neurosciences (ADHD) in 2025. Negev Labs offers investors early access to scalable therapies poised for strong clinical and financial outcomes.

The Round


Raising $7M to finalise two major company launches by mid-2025. Over 60% of the round is already secured.

”At Negev Labs, we're pioneering safe, transformative neurotherapies to enhance cognitive health and emotional well-being—efficiently unlocking value for our investors by rapidly advancing validated drug candidates toward critical milestones.”


—  Shlomi Raz, Managing Partner

Upcoming Information Session


Join us for "Beyond the Fund: How Biotech Venture Builders Are Redefining Early-Stage Innovation," a 60-minute webinar exploring why leading biotech investors are turning from traditional VC funds to venture builder models.

Hear from industry veterans, experienced founders, and LPs about what's working (and what's not) with this new approach—alongside a live investment pitch from Negev Labs.


Limited spaces available—register now to secure your spot.


Date: 29th May 2025

Time: 3:00 PM BST


Rebroadcast for Singapore & Australia Audience will also be available on 30th May 2025 at 4:00 PM AEST / 2:00 PM SGT

Register Your Interest Today


Register your interest today to access Negev Labs’ high-growth biotech opportunity.

WI CORPORATE SPONSORS


Comments

Popular posts from this blog

The RADIO framework provides a strong foundation for designing APIs and system integrations with consistency and maintainability in mind

Whooping cough is an illness that can spread easily. It's also called pertussis

Developing User Interfaces with GitHub Copilot